Lower GIs: Trends & Opportunities in Laxatives, Antidiarrhoeals, Probiotics, Antispasmodics & IBS remedies

The dynamic Lower GIs category - laxatives, antidiarrhoeals, antispasmodics & IBS remedies (plus GI-oriented probiotics) - is currently outperforming the consumer health market overall.

Our new report delves into this important growth category, picking out the underlying trends that can make or break a brand in the fiercely competitive landscape. Individual country profiles covering the biggest global markets for Lower GIs assess the performance of key brands and companies via comprehensive analysis and a range of charts showing sales and growth.

Data analysis within each country profile includes a breakdown of laxatives and antidiarrhoeals sales by segment, while charts in the diverse GI-oriented probiotics category show the key positionings of leading brands. Dynamic areas going forward are assessed, with insights into key opportunities.

Dedicated case studies of exciting brands cover the innovations, line extensions, new formats and consumer promotional activity that have made them a success.

ByMyEye

As an added benefit this report features exclusive research from BeMyEye examining key pharmacist brand recommendations (including primary and secondary recommendations across categories, plus reasons for recommending) in key European markets.

BeMyEye is a leading crowdsourced perfect store data as a service (DAAS) provider. Operating in 20 countries, it tracks Perfect Store execution metrics, including brand recommendations, by deploying over 1.5mn on-demand data gatherers using the BeMyEye App, and leveraging cutting-edge technologies to analyse the data.

Key features of the report:

• An in-depth exploration of the Lower GIs market, including Laxatives, Antidiarrhoeals Antispasmodic & IBS remedies and Probiotics

• Landscaping 10 major markets from across the globe, with topline sales, brand performances, regulatory developments, launches and ad campaigns

• Shorter summaries of main activity and trends in additional markets, including Australia, Canada, UK, Poland and Spain

• Mid-2018 sales from newly-updated DB6, our dedicated OTC sales database

• Pharmacist brand recommendations in key European markets, courtesy of BeMyEye

• Case studies of key brands like Biostime and Metamucil, highlighting success factors, sales, NPD and A+P activity, plus a section casting a spotlight on innovations

• Forecast sales for all categories and countries, plus a look at what the future holds

10 individual markets profiled:

Brazil China France Germany India

Italy Japan Mexico Russia USA

LOWER GIs

• Growth drivers, success factors and competitive landscape

• In-depth category analysis across multiple markets

• Forecast sales for all categories, plus a look to what the future holds

Table of Contents

Definitions & methodology

Executive Summary (30 pages)

• Global overview
• Opportunities abound in high-growth market
• Lower GIs sales mid-2017 & mid-2018
• Lower GIs sales by region mid-2018
• Lower GIs sales by category mid-2018
• Leading lower GIs markets mid-2018
• Leading lower GIs brands 2017
• Lower GIs players
• Sanofi tops fragmented lower GIs market
• Leading lower GIs marketers 2017
• Major M&A activity shakes up Lower GIs market
• Laxatives hit by lack of innovation
• Laxatives sales mid-2017 & mid-2018
• Laxatives brand recommendations from pharmacists in key European markets
• Reasons for recommendation
• Antidiarrhoeals growing well in USA, emerging markets
• Antidiarrhoeals sales mid-2017 & mid-2018
• Antidiarrhoeals brand recommendations from pharmacists in key European markets
• Reasons for recommendation
• Antispasmodics & IBS remedies slowly developing worldwide
• Antispasmodics & IBS remedies sales mid-2017 & mid-2018
• Antispasmodics & IBS remedies brand recommendations from pharmacists in key European markets
• Reasons for recommendation
• Probiotics a dynamic, rapidly-expanding category
• Probiotics sales mid-2017 & mid-2018
• Probiotics brand recommendations from pharmacists in key European markets
• Reasons for recommendation
• Prospects for lower GIs
• Global lower GIs forecast sales 2022-27
• Global lower GIs forecast sales by category 2022-27
• Opportunities & threats

Brazil (15 pages)

• Overview (3pp)
• Brazil lower GIs sales mid-2017 & mid-2018
• Topline lower GIs trends
• Brazil lower GIs sales by category mid-2018
• Brazil leading lower GIs marketers mid-2018
• Brazil leading lower GIs brands mid-2018
• Laxatives (4pp)
• Trends & developments in laxatives
• Brazil laxatives sales mid-2017 & mid-2018
• Brazil leading laxatives mid-2018
• Brazil laxatives sales by segment 2017
• Tamarine and Naturetti jelly impacted by shortages
• Antidiarrhoeals (2pp)
• Trends & developments in antidiarrhoeals
• Brazil antidiarrhoeals sales mid-2017 & mid-2018
• Brazil leading antidiarrhoeals mid-2018
• Antispasmodics & IBS remedies (1p)
• Trends & developments in antispasmodics & IBS remedies
• Brazil antispasmodics & IBS remedies sales mid-2017 & mid-2018
• Brazil leading antispasmodics & IBS remedies mid-2018
• Probiotics (4pp)
• Trends & developments in probiotics
• Brazil probiotics sales mid-2017 & mid-2018
• Brazil leading probiotics mid-2018
• Positioning for probiotics in Brazil
• Outlook (1p)
• New niche launches to drive growth
• Brazil lower GIs forecast sales 2022-27
• Brazil lower GIs forecast sales by category 2022-27

China (14 pages)

• Overview (3pp)
• China lower GIs sales mid-2017 & mid-2018
• Topline lower GIs trends
• China lower GIs sales by category mid-2018
• China leading lower GIs marketers mid-2018
• China leading lower GIs brands mid-2018
• Laxatives (3pp)
• Trends & developments in laxatives
• China laxatives sales mid-2017 & mid-2018
• China leading laxatives mid-2018
• China laxatives sales by segment 2017
• Antidiarrhoeals (3pp)
• Trends & developments in antidiarrhoeals
• China antidiarrhoeals sales mid-2017 & mid-2018
• China leading antidiarrhoeals mid-2018
• China antidiarrhoeals sales by ingredient segment 2017
• Probiotics (4pp)
• Trends & developments in probiotics
• China probiotics sales mid-2017 & mid-2018
• China leading probiotics mid-2018
• Positioning for probiotics in China
• Outlook (1p)
• Paediatric segment offers one route to growth
• China lower GIs forecast sales 2022-27
• China lower GIs forecast sales by category 2022-27

France (17 pages)

• Overview (3pp)
• France lower GIs sales mid-2017 & mid-2018
• Topline lower GIs trends
• France lower GIs sales by category mid-2018
• France leading lower GIs marketers mid-2018
• France leading lower GIs brands mid-2018
• Laxatives (4pp)
• Trends & developments in laxatives
• France laxatives sales mid-2017 & mid-2018
• France leading laxatives mid-2018
• France laxatives sales by segment 2017
• Colon cleansers reverse-switched
• Antidiarrhoeals (3pp)
• Trends & developments in antidiarrhoeals
• France antidiarrhoeals sales mid-2017 & mid-2018
• France leading antidiarrhoeals mid-2018
• France antidiarrhoeals sales by ingredient segment 2017
• Nifuroxazide to be reverse-switched?
• Antispasmodics & IBS remedies (2pp)
• Trends & developments in antispasmodics & IBS remedies
• France antispasmodics & IBS remedies sales mid-2017 & mid-2018
• France leading antispasmodics & IBS remedies mid-2018
• Probiotics (4pp)
• Trends & developments in probiotics
• France probiotics sales mid-2017 & mid-2018
• France leading probiotics mid-2018
• Positioning for probiotics in France
• EU: Saccharomyces boulardii contra-indications implemented
• Outlook (1p)
• Transition to pure OTC category should boost sales
• France lower GIs forecast sales 2022-27
• France lower GIs forecast sales by category 2022-27

Germany (15 pages)

• Overview (3pp)
• Germany lower GIs sales mid-2017 & mid-2018
• Topline lower GIs trends
• Germany lower GIs sales by category mid-2018
• Germany leading lower GIs marketers mid-2018
• Germany leading lower GIs brands mid-2018
• Laxatives (3pp)
• Trends & developments in laxatives
• Germany laxatives sales mid-2017 & mid-2018
• Germany leading laxatives mid-2018
• Germany laxatives sales by segment 2017
• Antidiarrhoeals (2pp)
• Trends & developments in antidiarrhoeals
• Germany antidiarrhoeals sales mid-2017 & mid-2018
• Germany leading antidiarrhoeals mid-2018
• Germany antidiarrhoeals sales by ingredient segment 2017
• Antispasmodics & IBS remedies (1p)
• Trends & developments in antispasmodics & IBS remedies
• Germany antispasmodics & IBS remedies sales mid-2017 & mid-2018
• Germany leading antispasmodics & IBS remedies mid-2018
• Probiotics (5pp)
• Trends & developments in probiotics
• Germany probiotics sales mid-2017 & mid-2018
• Germany leading probiotics mid-2018
• Positioning for probiotics in Germany
• Outlook (1p)
• Bright future, particularly for probiotics
• Germany lower GIs forecast sales 2022-27
• Germany lower GIs forecast sales by category 2022-27

India (15 pages)

• Overview (3pp)
• India lower GIs sales mid-2017 & mid-2018
• Topline lower GIs trends
• India lower GIs sales by category mid-2018
• India leading lower GIs marketers mid-2018
• India leading lower GIs brands mid-2018
• Laxatives (3pp)
• Trends & developments in laxatives
• India laxatives sales mid-2017 & mid-2018
• India leading laxatives mid-2018
• India laxatives sales by segment 2017
• Antidiarrhoeals (3pp)
• Trends & developments in antidiarrhoeals
• India antidiarrhoeals sales mid-2017 & mid-2018
• India leading antidiarrhoeals mid-2018
• India antidiarrhoeals sales by ingredient segment 2017
• Diarrhoea continues to be big problem in India
• Antispasmodics & IBS remedies (1p)
• Trends & developments in antispasmodics & IBS remedies
• India antispasmodics & IBS remedies sales mid-2017 & mid-2018
• India leading antispasmodics & IBS remedies mid-2018
• Probiotics (4pp)
• Trends & developments in probiotics
• India probiotics sales mid-2017 & mid-2018
• India leading probiotics mid-2018
• Positioning for probiotics in India
• Outlook (1p)
• Diversification in A+P and positionings will drive growth
• India lower GIs forecast sales 2022-27
• India lower GIs forecast sales by category 2022-27

Italy (15 pages)

• Overview (3pp)
• Italy lower GIs sales mid-2017 & mid-2018
• Topline lower GIs trends
• Italy lower GIs sales by category mid-2018
• Italy leading lower GIs marketers mid-2018
• Italy leading lower GIs brands mid-2018
• Laxatives (3pp)
• Trends & developments in laxatives
• Italy laxatives sales mid-2017 & mid-2018
• Italy leading laxatives mid-2018
• Italy laxatives sales by segment 2017
• Antidiarrhoeals (2pp)
• Trends & developments in antidiarrhoeals
• Italy antidiarrhoeals sales mid-2017 & mid-2018
• Italy leading antidiarrhoeals mid-2018
• Italy antidiarrhoeals sales by ingredient segment 2017
• Antispasmodics & IBS remedies (2pp)
• Trends & developments in antispasmodics & IBS remedies
• Italy antispasmodics & IBS remedies sales mid-2017 & mid-2018
• Italy leading antispasmodics & IBS remedies mid-2018
• Probiotics (4pp)
• Trends & developments in probiotics
• Italy probiotics sales mid-2017 & mid-2018
• Italy leading probiotics mid-2018
• Positioning for probiotics in Italy
• Outlook (1p)
• Broadening positionings will drive growth
• Italy lower GIs forecast sales 2022-27
• Italy lower GIs forecast sales by category 2022-27

Japan (14 pages)

• Overview (3pp)
• Japan lower GIs sales mid-2017 & mid-2018
• Topline lower GIs trends
• Japan lower GIs sales by category mid-2018
• Japan leading lower GIs marketers mid-2018
• Japan leading lower GIs brands mid-2018
• Laxatives (3pp)
• Trends & developments in laxatives
• Japan laxatives sales mid-2017 & mid-2018
• Japan leading laxatives mid-2018
• Japan laxatives sales by segment 2017
• Antidiarrhoeals (2pp)
• Trends & developments in antidiarrhoeals
• Japan antidiarrhoeals sales mid-2017 & mid-2018
• Japan leading antidiarrhoeals mid-2018
• Japan antidiarrhoeals sales by ingredient segment 2017
• Antispasmodics & IBS remedies (1p)
• Trends & developments in antispasmodics & IBS remedies
• Japan antispasmodics & IBS remedies sales mid-2017 & mid-2018
• Japan leading antispasmodics & IBS remedies mid-2018
• Probiotics (4pp)
• Trends & developments in probiotics
• Japan probiotics sales mid-2017 & mid-2018
• Japan leading probiotics mid-2018
• Positioning for probiotics in Japan
• Outlook (1p)
• Revival of probiotics will drive growth
• Japan lower GIs forecast sales 2022-27
• Japan lower GIs forecast sales by category 2022-27

Mexico (17 pages)

• Overview (3pp)
• Mexico lower GIs sales mid-2017 & mid-2018
• Topline lower GIs trends
• Mexico lower GIs sales by category mid-2018
• Mexico leading lower GIs marketers mid-2018
• Mexico leading lower GIs brands mid-2018
• Laxatives (3pp)
• Trends & developments in laxatives
• Mexico laxatives sales mid-2017 & mid-2018
• Mexico leading laxatives mid-2018
• Mexico laxatives sales by segment 2017
• Antidiarrhoeals (3pp)
• Trends & developments in antidiarrhoeals
• Mexico antidiarrhoeals sales mid-2017 & mid-2018
• Mexico leading antidiarrhoeals mid-2018
• Mexico antidiarrhoeals sales by ingredient segment 2017
• Antispasmodics & IBS remedies (2pp)
• Trends & developments in antispasmodics & IBS remedies
• Mexico antispasmodics & IBS remedies sales mid-2017 & mid-2018
• Mexico leading antispasmodics & IBS remedies mid-2018
• Probiotics (5pp)
• Trends & developments in probiotics
• Mexico probiotics sales mid-2017 & mid-2018
• Mexico leading probiotics mid-2018
• Positioning for probiotics in Mexico
• Outlook (1p)
• Steady growth driven by dynamic probiotics
• Mexico lower GIs forecast sales 2022-27
• Mexico lower GIs forecast sales by category 2022-27

Russia (16 pages)

• Overview (3pp)
• Russia lower GIs sales mid-2017 & mid-2018
• Topline lower GIs trends
• Russia lower GIs sales by category mid-2018
• Russia leading lower GIs marketers mid-2018
• Russia leading lower GIs brands mid-2018
• Laxatives (3pp)
• Trends & developments in laxatives
• Russia laxatives sales mid-2017 & mid-2018
• Russia leading laxatives mid-2018
• Russia laxatives sales by segment 2017
• Antidiarrhoeals (3pp)
• Trends & developments in antidiarrhoeals
• Russia antidiarrhoeals sales mid-2017 & mid-2018
• Russia leading antidiarrhoeals mid-2018
• Russia antidiarrhoeals sales by ingredient segment 2017
• Antispasmodics & IBS remedies (2pp)
• Trends & developments in antispasmodics & IBS remedies
• Russia antispasmodics & IBS remedies sales mid-2017 & mid-2018
• Russia leading antispasmodics & IBS remedies mid-2018
• Probiotics (4pp)
• Trends & developments in probiotics
• Russia probiotics sales mid-2017 & mid-2018
• Russia leading probiotics mid-2018
• Positioning for probiotics in Russia
• Outlook (1p)
• Rising to generic challenge essential for leading brands
• Russia lower GIs forecast sales 2022-27
• Russia lower GIs forecast sales by category 2022-27

USA (19 pages)

• Overview (3pp)
• USA lower GIs sales mid-2017 & mid-2018
• Topline lower GIs trends
• USA lower GIs sales by category mid-2018
• USA leading lower GIs marketers mid-2018
• USA leading lower GIs brands mid-2018
• Laxatives (5pp)
• Trends & developments in laxatives
• USA laxatives sales mid-2017 & mid-2018
• USA leading laxatives mid-2018
• USA laxatives sales by segment 2017
• Antidiarrhoeals (4pp)
• Trends & developments in antidiarrhoeals
• USA antidiarrhoeals sales mid-2017 & mid-2018
• USA leading antidiarrhoeals mid-2018
• FDA limits loperamide packaging to allay safety concerns
• USA antidiarrhoeals sales by ingredient segment 2017
• Probiotics (6pp)
• Trends & developments in probiotics
• USA probiotics sales mid-2017 & mid-2018
• USA leading probiotics mid-2018
• Positioning for probiotics in USA
• Outlook (1p)
• New positionings needed to keep growth high
• USA lower GIs forecast sales 2022-27
• USA lower GIs forecast sales by category 2022-27

Selected Markets in Brief

Australia (7 pages)

• Australia lower GIs sales mid-2017 & mid-2018
• Topline lower GIs trends
• Australia lower GIs sales by category mid-2018
• Australia leading lower GIs marketers mid-2018
• Australia leading laxatives mid-2018
• Australia leading antidiarrhoeals mid-2018
• Australia leading antispasmodics & IBS remedies mid-2018
• Australia leading probiotics mid-2018
• High level of launch activity in probiotics
• Probiotics to grow well
• Australia lower GIs forecast sales 2022-27
• Australia lower GIs forecast sales by category 2022-27

Canada (6 pages)

• Canada lower GIs sales mid-2017 & mid-2018
• Topline lower GIs trends
• Canada lower GIs sales by category mid-2018
• Canada leading lower GIs marketers mid-2018
• Canada leading laxatives mid-2018
• Canada leading antidiarrhoeals mid-2018
• Canada leading probiotics mid-2018
• Portfolio diversification key
• Canada lower GIs forecast sales 2022-27
• Canada lower GIs forecast sales by category 2022-27

Poland (6 pages)

• Poland lower GIs sales mid-2017 & mid-2018
• Topline lower GIs trends
• Poland lower GIs sales by category mid-2018
• Poland leading lower GIs marketers mid-2018
• Poland leading laxatives mid-2018
• Poland leading antidiarrhoeals mid-2018
• Poland leading antispasmodics & IBS remedies mid-2018
• Poland leading probiotics mid-2018
• Broadening range of benefits to strengthen established brands
• Poland lower GIs forecast sales 2022-27
• Poland lower GIs forecast sales by category 2022-27

Spain (6 pages)

• Spain lower GIs sales mid-2017 & mid-2018
• Topline lower GIs trends
• Spain lower GIs sales by category mid-2018
• Spain leading lower GIs marketers mid-2018
• Spain leading laxatives mid-2018
• Spain leading antidiarrhoeals mid-2018
• Spain leading antispasmodics & IBS remedies mid-2018
• Spain leading probiotics mid-2018
• Increased consumer awareness of products will boost sales
• Spain lower GIs forecast sales 2022-27
• Spain lower GIs forecast sales by category 2022-27

UK (6 pages)

• UK lower GIs sales mid-2017 & mid-2018
• Topline lower GIs trends
• UK lower GIs sales by category mid-2018
• UK leading lower GIs marketers mid-2018
• UK leading laxatives mid-2018
• UK leading antidiarrhoeals mid-2018
• UK leading antispasmodics & IBS remedies mid-2018
• UK leading probiotics mid-2018
• NPD key to unlocking growth
• UK lower GIs forecast sales 2022-27
• UK lower GIs forecast sales by category 2022-27

Brand Case Studies (10 pages)

• Villicote positioned to restore intestinal lining
• BloXair combines simethicone with probiotics to treat bloating
• IBGard's “Site-specific technology” to improve efficacy
• Vital Foods offers kiwi-based natural laxative and digestive health range
• Qiara probiotic range derived from breast milk
• Detoxner offers range of treatments for IBS and associated symptoms
• Ganeden BC30 a stable probiotic strain opening up probiotic-enriched foods
• China's No.1 Biostime applies probiotic expertise to Australia's infant nutrition market
• Biostime probiotic sales mid-2017 & mid-2018
• P&G builds digestive health brand family to boost equity of laxatives and probiotics

Outlook (12 pages)

• Prospects for lower GIs
• Global lower GIs forecast sales 2022-27
• Global lower GIs forecast sales by category 2022-27
• Global lower GIs forecast sales by region 2022-27
• Spotlight on prospects for probiotics
• Regional outlook
• Asia-Pacific lower GIs forecast sales by category 2022-27
• Asia-Pacific lower GIs forecast sales by country 2022-27
• North America lower GIs forecast sales by category 2022-27
• North America lower GIs forecast sales by country 2022-27
• Western Europe lower GIs forecast sales by category 2022-27
• Western Europe lower GIs forecast sales by country 2022-27
• C&E Europe lower GIs forecast sales by category 2022-27
• C&E Europe lower GIs forecast sales by country 2022-27
• Latin America lower GIs forecast sales by category 2022-27
• Latin America lower GIs forecast sales by country 2022-27
• Opportunities & threats